rian.ie - Results

A A A

Current Search:	'Cancer' in all fields;

Displaying Results 226 - 250 of 3206 on page 10 of 129

Mark

Cancer mortality in Ireland: 1976-1986. (1987)

Seymour, Colin; Herity, Bernadette; Moriarty, Michael J.

Mark

Preoperative chemoradiation with paclitaxel-carboplatin or with fluorouracil-oxaliplatin-folinic acid (FOLFOX) for resectable esophageal and junctional cancer: the PROTECT-1402, randomized phase 2 trial. (2016)

Messager, Mathieu; Mirabel, Xavier; Tresch, Emmanuelle; Paumier, Amaury; Vendrely, Véro...

Messager, Mathieu; Mirabel, Xavier; Tresch, Emmanuelle; Paumier, Amaury; Vendrely, Véronique; Dahan, Laetitia; Glehen, Olivier; Vasseur, Frederique; Lacornerie, Thomas; Piessen, Guillaume; El Hajbi, Farid; Robb, William B; Clisant, Stéphanie; Kramar, Andrew; Mariette, Christophe; Adenis, Antoine

Abstract:

The original article is available at www.biomedcentral.com
BACKGROUND: Often curative treatment for locally advanced resectable esophageal or gastro-esophageal junctional cancer consists of concurrent neoadjuvant radiotherapy and chemotherapy followed by surgery. Currently, one of the most commonly used chemotherapy regimens in this setting is a combination of a fluoropyrimidin and of a platinum analogue. Due to the promising results of the recent CROSS trial, another regimen combining paclitaxel and carboplatin is also widely used by European and American centers. No clinical study has shown the superiority of one treatment over the other. The objective of this Phase II study is to clarify clinical practice by comparing these two chemotherapy treatments. Our aim is to evaluate, in operable esophageal and gastro-esophageal junctional cancer, the complete resection rate and severe postoperative morbidity rate associated with these two neoadjuvant chemo...

https://epubs.rcsi.ie/surgart/32

Mark

Integrating Colon Cancer Microarray Data: Associating Locus-Specific Methylation Groups to Gene Expression-Based Classifications (2015)

Barat, Ana; Ruskin, Heather J; Byrne, Annette T; Prehn, Jochen HM

Mark

The relevance of using 3D cell cultures, in addition to 2D monolayer cultures, when evaluating breast cancer drug sensitivity and resistance. (2016)

O'Driscoll, Lorraine

Mark

Identification of pancreatic cancer invasion-related proteins by proteomic analysis (2009)

Walsh, Naomi; O'Donovan, Norma; Kennedy, Susan; Henry, Michael; Meleady, Paula; Cl...

Mark

A promising set of candidate biomarkers of radioresistant prostate cancer (2016)

Mc Dermott, Niamh

Mark

In two minds about screening: an investigation of cervical cancer prevention among Irish women (2016)

Kotzur, Marie-Christin

Mark

Promotion of a cancer-like phenotype, through chronic exposure to inflammatory cytokines and hypoxia in a bronchial epithelial cell line model. (2016)

GRAY, STEVEN; O'BYRNE, KEN; BAIRD, ANNE-MARIE

Mark

Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies. (2017)

Toomey, Sinead; Eustace, Alex J; Fay, Joanna; Sheehan, Katherine M; Carr, Aoife; Milews...

Toomey, Sinead; Eustace, Alex J; Fay, Joanna; Sheehan, Katherine M; Carr, Aoife; Milewska, Malgorzata; Madden, Stephen F; Teiserskiene, Ausra; Kay, Elaine W; O'Donovan, Norma; Gallagher, William; Grogan, Liam; Breathnach, Oscar; Walshe, Janice; Kelly, Catherine; Moulton, Brian; Kennedy, M John; Gullo, Guiseppe; Hill, Arnold DK; Power, Colm

Abstract:

The original article is available at www.biomedcentral.com
BACKGROUND: The Cancer Genome Atlas analysis revealed that somatic EGFR, receptor tyrosine-protein kinase erbB-2 (ERBB2), Erb-B2 receptor tyrosine kinase 3 (ERBB3) and Erb-B2 receptor tyrosine kinase 4 (ERBB4) gene mutations (ERBB family mutations) occur alone or co-occur with somatic mutations in the gene encoding the phosphatidylinositol 3-kinase (PI3K) catalytic subunit (PIK3CA) in 19% of human epidermal growth factor receptor 2 (HER2)-positive breast cancers. Because ERBB family mutations can activate the PI3K/AKT pathway and likely have similar canonical signalling effects to PI3K pathway mutations, we investigated their combined impact on response to neoadjuvant HER2-targeted therapies. METHODS: Baseline tumour biopsies were available from 74 patients with HER2-positive breast cancer who were enrolled in the phase II TCHL neoadjuvant study (ICORG 10-05) assessing TCH (...

https://epubs.rcsi.ie/molmedart/35

Mark

Patients’ bowel symptom experiences and self-care strategies following sphincter-saving surgery for rectal cancer (2014)

Landers, Margaret; McCarthy, Geraldine; Livingstone, Vicki; Savage, Eileen

Mark

Formulation and evaluation of anisamide-targeted amphiphilic cyclodextrin nanoparticles to promote therapeutic gene silencing in a 3D prostate cancer bone metastases model (2016)

Evans, James C.; Malhotra, Meenakshi; Fitzgerald, Kathleen A.; Guo, Jianfeng; Cronin, M...

Mark

Gold nanoparticles enlighten the future of cancer theranostics (2017)

Guo, Jianfeng; Rahme, Kamil; He, Yan; Li, Lin-Lin; Holmes, Justin D.; O'Driscoll, ...

Mark

Dye-doped silica nanoparticles for cancer cell staining and detection (2017)

O'Connell, Claire

Mark

“The generation of anti-prostate cancer-specific antibodies for improved disease diagnosis” (2016)

Byrne, Hannah

Mark

Knowledge, attitudes, and practices regarding cervical cancer and screening among women visiting primary health care Centres in Bahrain. (2018)

Jassim, Ghufran A; Obeid, Alaaeddin; Al Nasheet, Huda A

Mark

SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival. (2017)

Mohelnikova-Duchonova, Beatrice; Strouhal, Ondrej; Hughes, David J; Holcatova, Ivana; O...

SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival. (2017)

Mohelnikova-Duchonova, Beatrice; Strouhal, Ondrej; Hughes, David J; Holcatova, Ivana; Oliverius, Martin; Kala, Zdenek; Campa, Daniele; Rizzato, Cosmeri; Canzian, Federico; Pezzilli, Raffaele; Talar-Wojnarowska, Renata; Malecka-Panas, Ewa; Sperti, Cosimo; Federico Zambon, Carlo; Pedrazzoli, Sergio; Fogar, Paola; Milanetto, Anna Caterina; Capurso, Gabriele; Delle Fave, Gianfranco; Valente, Roberto

Abstract:

The original article is available at www.nature.com
Expression of the solute carrier (SLC) transporter SLC22A3 gene is associated with overall survival of pancreatic cancer patients. This study tested whether genetic variability in SLC22A3 associates with pancreatic cancer risk and prognosis. Twenty four single nucleotide polymorphisms (SNPs) tagging the SLC22A3 gene sequence and regulatory elements were selected for analysis. Of these, 22 were successfully evaluated in the discovery phase while six significant or suggestive variants entered the validation phase, comprising a total study number of 1,518 cases and 3,908 controls. In the discovery phase, rs2504938, rs9364554, and rs2457571 SNPs were significantly associated with pancreatic cancer risk. Moreover, rs7758229 associated with the presence of distant metastases, while rs512077 and rs2504956 correlated with overall survival of patients. Although replicated, the association for rs9364554 did no...

https://epubs.rcsi.ie/physiolart/133